Research Article

Xanthine Oxidase Activity in Type 2 Diabetes Mellitus Patients with and without Diabetic Peripheral Neuropathy

Table 2

Serum XOD activity, uric acid, IMA, and other biomarkers of protein modifications in control subjects and type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy.

Control subjects ()Type 2 DM patients
Non-DPN ()DPN ()

XOD (U/L)5.7 ± 2.420.3 ± 8.27.5 ± 10.
IMA (IU/mL)28.5 ± 8.734.7 ± 12.40.3 ± 11.
Albumin (g/L)44.1 ± 2.443.4 ± 2.242.1 ± 2.
HbA1c (mmol/mol)35.2 ± 11.859.2 ± 22.72.7 ± 22.
Uric acid (μmol/L)246 ± 70268 ± 72298 ± 6
Total thiols (μmol/L)541 ± 94407 ± 11294 ± 8
AGE (RFU)6.41 ± 1.197.26 ± 1.48.45 ± 2.1
AOPP (μmol/L Chloramine-T)38.7 ± 9.463.7 ± 23.65.3 ± 26.

Data are presented as mean values ± standard deviation. Differences between groups were tested by one-way ANOVA and post hoc Student’s -test. XOD: xanthine oxidase; IMA: ischemia-modified albumin; AGE: advanced glycation end products; AOPP: advanced protein oxidation products; RFU: relative fluorescence units.
versus control group; versus non-DPN group.